Brincidofovir

Kathryn Dzintars, Pharm.D., BCPS
Brincidofovir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of human smallpox disease in adults and pediatric patients, including neonates
  • Approved by the FDA in June 2021 for the treatment of smallpox through the FDA Animal Rule.
    • It is NOT available for commercial sale, but Chimerix will work globally with public health agencies in the event the medication is needed for a smallpox outbreak.

NON-FDA APPROVED USES

  • Chimerix transferred exclusive rights for the development of brincidofovir for other indications (e.g., adenovirus) to SymBio Pharmaceuticals Ltd in 2019.
    • Any requests for brincidofovir other than for smallpox should be submitted to SymBio.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of human smallpox disease in adults and pediatric patients, including neonates
  • Approved by the FDA in June 2021 for the treatment of smallpox through the FDA Animal Rule.
    • It is NOT available for commercial sale, but Chimerix will work globally with public health agencies in the event the medication is needed for a smallpox outbreak.

NON-FDA APPROVED USES

  • Chimerix transferred exclusive rights for the development of brincidofovir for other indications (e.g., adenovirus) to SymBio Pharmaceuticals Ltd in 2019.
    • Any requests for brincidofovir other than for smallpox should be submitted to SymBio.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: June 23, 2022